HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13
HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $14 to $13.
TCR2 Therapeutics Announces Topline Results From Phase 1 Portion Of gavo-cel Phase 1/2 Trial; Showed ‘Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%’
- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit
- Second RECIST partial response in ovarian cancer supports
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.